A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT05590377. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Modakafusp Alfa in Combination With Daratumumab Subcutaneous in Patients With Relapsed or Refractory Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main aim of this study is to determine safety and tolerability of modakafusp alfa given together with daratumumab to find out the best treatment dose. Another aim of this study is to learn more about the characteristics of modakafusp alfa.
Study identification
- NCT ID
- NCT05590377
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 15 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 22, 2023
- Primary completion
- May 21, 2024
- Completion
- May 21, 2024
- Last update posted
- Jan 29, 2026
2023 – 2024
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 77598 | — |
| Fort Wayne Medical Oncology and Hematology, Inc | Fort Wayne | Indiana | 46060 | — |
| HCA Midwest Health (Midwest Ventures Group HCA MidAmerica Division) | Overland Park | Kansas | 66211 | — |
| Tulane University Health Sciences Center | New Orleans | Louisiana | 70112 | — |
| Floating Hospital for Children at Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Washington University School of Medicine | St Louis | Missouri | 63130 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Summit Medical Group PA | Florham Park | New Jersey | 07932 | — |
| New York Cancer and Blood Specialists | Bay Shore | New York | 11706 | — |
| Stony Brook University Hospital | Stony Brook | New York | 11794 | — |
| University of Cincinnati - Vontz Center for Molecular Studies | Cincinnati | Ohio | 45267 | — |
| Tranquil Clinical Research | Webster | Texas | 78041 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05590377, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 29, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05590377 live on ClinicalTrials.gov.